By Myles Starr
Immunocompromised people have a higher risk for infection with the herpes zoster virus (HZV) and complications like postherpetic neuralgia, which is why early this year, the CDC and the Advisory Committee on Immunization Practices (ACIP) recommended two doses of the recombinant HZV vaccine (RZV; Shingrix, GlaxoSmithKline) for people 19 years of age and older with weakened immune systems. This expands its previous recommendation for RZV vaccination in immunocompetent adults ages 50